Stock Events

Stock Events

Celldex Therapeutics 

$41.22
22
+$0.65+1.6% Tuesday 20:00
+$0.00+0%Tuesday 20:37After hours

Statistics

Day High
41.25
Day Low
41.19
52W High
45.14
52W Low
21.34
Volume
32,076
Avg. Volume
-
Mkt Cap
3.24B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.18
-1.02
-0.87
-0.71
Expected EPS
-1.016177
Actual EPS
N/A

Financials

-16,748.03%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.55MRevenue
-258.76MNet Income

Analyst Ratings

57.00Average Price Target
The highest estimate is 100.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLDX. It's not an investment recommendation.
NVIDIA
7
NVDA
Amazon
6
AMZN
Microsoft
5
MSFT
Tesla
5
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol-Myers Squibb competes in the oncology and immunology sectors, similar to Celldex's focus on cancer and immune-related diseases.
Merck
MRK
Mkt Cap376.37B
Merck is a leading company in cancer treatment with its blockbuster drug Keytruda, directly competing with Celldex's cancer therapies.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences has a strong presence in the oncology and immunology markets, areas where Celldex is actively developing treatments.
AMGEN
AMGN
Mkt Cap237.52B
Amgen focuses on innovative therapeutics in oncology and other areas, overlapping with Celldex's therapeutic development programs.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals is involved in developing monoclonal antibodies for cancer and inflammatory diseases, competing with Celldex's pipeline.
Incyte
INCY
Mkt Cap25.91B
Incyte operates in the oncology sector, particularly in developing therapies for cancer, which competes with Celldex's focus areas.
Exelixis
EXEL
Mkt Cap13.4B
Exelixis is focused on the discovery, development, and commercialization of new medicines for cancer treatment, directly competing with Celldex.
Novartis
NVS
Mkt Cap301.95B
Novartis is a global healthcare company that has a strong focus on innovative medicines in oncology, competing with Celldex's cancer therapies.
Pfizer
PFE
Mkt Cap159.99B
Pfizer has a broad portfolio including oncology, competing in the same therapeutic areas as Celldex, especially in cancer treatment.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca has a significant presence in oncology, with a pipeline that includes treatments for various cancers, competing with Celldex's offerings.

About

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Show more...
CEO
Anthony S. Marucci
Employees
198
Country
United States
ISIN
US15117B2025
WKN
000A2PEAB

Listings

STU
DE
TCE2.STU
F
DE
TCE2.F
MU
DE
TCE2.MU
BOATS
BOATS
CLDX.BOATS

0 Comments

Share your thoughts

FAQ

What is Celldex Therapeutics stock price today?▼
The current price of CLDX is $41.22 USD — it has increased by +1.6% in the past 24 hours. Watch Celldex Therapeutics stock price performance more closely on the chart.
What is Celldex Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Celldex Therapeutics stocks are traded under the ticker CLDX.
Is Celldex Therapeutics stock price growing?▼
CLDX stock has fallen by -1.15% compared to the previous week, the month change is a +16.84% rise, over the last year Celldex Therapeutics has showed a +89.52% increase.
What is Celldex Therapeutics market cap?▼
Today Celldex Therapeutics has the market capitalization of 3.24B
When is the next Celldex Therapeutics earnings date?▼
Celldex Therapeutics is going to release the next earnings report on November 11, 2026.
What were Celldex Therapeutics earnings last quarter?▼
CLDX earnings for the last quarter are -0.94 USD per share, whereas the estimation was -1.06 USD resulting in a +11.03% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Celldex Therapeutics revenue for the last year?▼
Celldex Therapeutics revenue for the last year amounts to 1.55M USD.
What is Celldex Therapeutics net income for the last year?▼
CLDX net income for the last year is -258.76M USD.
How many employees does Celldex Therapeutics have?▼
As of August 26, 2026, the company has 198 employees.
In which sector is Celldex Therapeutics located?▼
Celldex Therapeutics operates in the Health & Wellness sector.
When did Celldex Therapeutics complete a stock split?▼
The last stock split for Celldex Therapeutics was on February 11, 2019 with a ratio of 1:15.
Where is Celldex Therapeutics headquartered?▼
Celldex Therapeutics is headquartered in HAMPTON, United States.